ARQL - ArQule, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
5.00
+0.01 (+0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close4.99
Open4.99
Bid4.50 x 800
Ask6.06 x 1200
Day's range4.77 - 5.07
52-week range0.94 - 6.07
Volume1,937,931
Avg. volume1,527,050
Market cap477.476M
Beta0.61
PE ratio (TTM)N/A
EPS (TTM)-0.36
Earnings date2 Aug 2018 - 6 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.10
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

    ArQule, Inc. (ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 23rd Congress of European Hematological Association (EHA) in Stockholm, Sweden. “Preliminary data from our Phase 1 dose escalation trial highlights the potential of ARQ 531 to become a new therapeutic option for patients with B-cell malignancies,” commented ArQule Chief Medical Officer and Head of Research and Development, Brian Schwartz, M.D. “There is a significant unmet need for patients with relapsed or refractory B-cell malignancies, in particular those with C481S-mediated resistance to irreversible BTK inhibitors such as ibrutinib.

  • Business Wire4 days ago

    ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

    ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 23rd Congress of European Hematological Association (EHA) in Stockholm, Sweden. “Preliminary data from our Phase 1 dose escalation trial highlights the potential of ARQ 531 to become a new therapeutic option for patients with B-cell malignancies,” commented ArQule Chief Medical Officer and Head of Research and Development, Brian Schwartz, M.D. “There is a significant unmet need for patients with relapsed or refractory B-cell malignancies, in particular those with C481S-mediated resistance to irreversible BTK inhibitors such as ibrutinib.

  • Business Wire5 days ago

    ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference on June 21, 2018, at 10:30am EDT at the St. Regis in New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Options Traders Expect Huge Moves in ArQule (ARQL) Stock
    Zacks8 days ago

    Options Traders Expect Huge Moves in ArQule (ARQL) Stock

    ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Business Wire12 days ago

    ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)

    ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA Congress in Stockholm, Sweden. ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).

  • Business Wire12 days ago

    ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)

    ArQule, Inc. (ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA Congress in Stockholm, Sweden. ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).

  • Business Wire19 days ago

    ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Jefferies 2018 Healthcare Conference on June 7, 2018, at 3:00 p.m. ET at the Grand Hyatt, New York, New York. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.

  • Here's Why ArQule Stock Rose as Much as 16.8% Today
    Motley Fool25 days ago

    Here's Why ArQule Stock Rose as Much as 16.8% Today

    The biopharma's incredible 2018 surge continues, but today's news is a little less exciting for investors.

  • Business Wire26 days ago

    ArQule Strengthens Executive Team with Two Key Appointments

    ArQule, Inc. (ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning. “We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci.

  • What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
    Zackslast month

    What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

    Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

  • Associated Presslast month

    ArQule: 1Q Earnings Snapshot

    On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Business Wirelast month

    ArQule Reports First Quarter 2018 Financial Results

    ArQule, Inc. today announced its financial results for the first quarter of 2018.

  • Business Wire2 months ago

    ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

    ArQule, Inc. (ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.

  • Business Wire2 months ago

    ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China

    ArQule, Inc. today announced that it has entered into an exclusive license agreement with Basilea Pharmaceutica International Limited to develop and commercialize derazantinib, a pan-FGFR inhibitor in the US, EU, Japan and rest of the world excluding the People’s Republic of China, Hong Kong, Macau and Taiwan, where Sinovant Sciences Ltd., a Roivant Sciences Ltd.

  • GlobeNewswire2 months ago

    Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

    Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ...

  • Globe Newswire2 months ago

    Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

    Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases. Ronald Scott, Chief Executive Officer, said: "We are very excited about this partnership with ArQule. Derazantinib is an ideal match for our existing clinical oncology portfolio.

  • Will ArQule (ARQL) Continue to Surge Higher?
    Zacks3 months ago

    Will ArQule (ARQL) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in ArQule, Inc. (ARQL)

  • Business Wire3 months ago

    ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

    ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 17th Annual Needham Healthcare Conference on March 27th, 2018, at 3:30 p.m.

  • ArQule (ARQL) in Focus: Stock Moves 15.6% Higher
    Zacks3 months ago

    ArQule (ARQL) in Focus: Stock Moves 15.6% Higher

    Shares of ArQule (ARQL) rose nearly 16% yesterday.

  • Business Wire3 months ago

    ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

    ArQule, Inc. today announced that pre-clinical and clinical data on the company’s pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place in Chicago from April 14-April 18.

  • Associated Press3 months ago

    ArQule reports 4Q loss

    The Burlington, Massachusetts-based company said it had a loss of 9 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Business Wire3 months ago

    ArQule Reports Fourth Quarter and Full Year 2017 Financial Results

    ArQule, Inc. today announced its financial results for the fourth quarter and full year of 2017.

  • Business Wire3 months ago

    ArQule to Present at the 30th Annual Roth Conference on March 12, 2018

    ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, will present at the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California.

  • Business Wire4 months ago

    ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

    ArQule, Inc. today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m.

  • Business Wire4 months ago

    ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018

    ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Leerink Partners 7th Annual Global Healthcare Conference on February 15th, 2018, at 9:00 a.m.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes